BGB-11417-204: Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia

Condition: Chronic Lymphocytic Leukemia

Sponsor: BeOne Medicines

Full Title
BGB-11417-204: A Multicenter, Open-Label, Phase 2 Study to Investigate the Efficacy and Safety of Sonrotoclax Combined With Zanubrutinib Compared With Zanubrutinib Monotherapy in Adult Patients With Previously Untreated Chronic Lymphocytic Leukemia

Study Treatment
Zanubrutinib +/- Sonrotoclax
BGB-11417 (sonrotoclax) is a highly potent and selective Bcl-2 protein inhibitor.
Zanubrutinib is a more selective covalent BTK inhibitor.

Eligibility/Info
Untreated chronic lymphocytic leukemia that requires first line systemic therapy.

Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.

Locations
Babylon Medical Oncology
Central Park Medical Oncology
Eastchester Cancer Center
Lake Success Medical Oncology
Nostrand Medical Oncology
Patchogue Medical Oncology
Port Jefferson Medical Oncology
Port Jefferson Station Medical Oncology
Riverhead Medical Oncology

Go To Trial Homepage